

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Furosemide Injection Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Specific target organ toxicity - : Category 2 (Kidney, Liver)
repeated exposure

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P260 Do not breathe mist or vapours.
Response:
P319 Get medical help if you feel unwell.

Furosemide Injection Formulation

Version 3.8 Revision Date: 30.09.2023 SDS Number: 657930-00015 Date of last issue: 04.04.2023
Date of first issue: 03.05.2016

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Furosemide	54-31-9	$\geq 5 - < 10$

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Nitrogen oxides (NO_x)
Carbon oxides

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Sulphur oxides
Chlorine compounds

- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

environment.

Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Furosemide	54-31-9	TWA	200 µg/m ³	Internal
		TWA	OEB 2 (>=100 - 1000 µg/m ³)	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Appearance	:	Aqueous solution
Colour	:	yellow
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Furosemide:

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg
LD50 (Dog): 2,000 mg/kg
LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous
LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Furosemide:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: positive
		Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: mammalian liver cells Result: negative
		Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive
		Test Type: In vitro sister chromatid exchange assay in mammalian cells Test system: Chinese hamster cells Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative
		Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Chinese hamster Application Route: Ingestion Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Furosemide:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	104 weeks
LOAEL	:	16 mg/kg body weight
Result	:	equivocal

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	2 Years
LOAEL	:	91 mg/kg body weight
Result	:	positive

Reproductive toxicity

Not classified based on available information.

Components:

Furosemide:

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion General Toxicity - Parent: NOAEL: 90 mg/kg body weight Result: No effects on reproduction parameters Test Type: One-generation reproduction toxicity study Species: Mouse Application Route: Ingestion General Toxicity - Parent: NOAEL: 200 mg/kg body weight Result: No effects on reproduction parameters
Effects on foetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion General Toxicity Maternal: LOAEL: 50 mg/kg body weight Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No embryotoxic effects, No teratogenic effects Test Type: Fertility/early embryonic development Species: Mouse Application Route: Ingestion General Toxicity Maternal: LOAEL: 25 mg/kg body weight Result: Maternal toxicity observed., Fetal effects Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight Developmental Toxicity: LOAEL: 12.5 mg/kg body weight Result: Maternal toxicity observed., Reduced number of viable fetuses Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion General Toxicity Maternal: LOAEL: 15 mg/kg body weight Result: Maternal toxicity observed., No effects on foetal development

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Furosemide:

Exposure routes	:	Ingestion
Target Organs	:	Kidney
Assessment	:	Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Furosemide:

Species	:	Dog
NOAEL	:	4 mg/kg
LOAEL	:	8 mg/kg
Application Route	:	Ingestion
Exposure time	:	12 Months
Target Organs	:	Kidney
Symptoms	:	Blood disorders
Remarks	:	Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Furosemide:

Inhalation	:	Remarks: May be harmful if inhaled.
Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Remarks: May cause eye irritation.
Ingestion	:	Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Furosemide:

Toxicity to fish	:	LC50: 500 mg/l Exposure time: 96 h
------------------	---	---------------------------------------

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Furosemide:

Partition coefficient: n-octanol/water : log Pow: 2.03

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-

SAFETY DATA SHEET

according to the Globally Harmonized System



Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.8	30.09.2023	657930-00015	Date of first issue: 03.05.2016

Material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN